- Ehave announced it will utilize BRSF’s tech in an upcoming ketamine clinical study
- BRSF’s tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more.
- The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics
Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission to modernize brain diagnostics with cutting-edge tech that bridges the widening gap in access to quality care. The company’s technology will be part of a ketamine clinical study conducted by Ehave, Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. To read Ehave’s full announcement regarding the Ketamine Clinical Trial, go to https://ibn.fm/VMu6o.
Ehave is a leading provider of digital therapeutics for the psychedelic and mental health sectors. The company’s primary goal is to improve standard care with digital therapeutics to prevent or treat brain disorders or diseases. By partnering with BRSF, they will leverage both data and AI to correlate biomarkers to identify chronic pain, depression, PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia.
The trial will begin the second half of 2021 and will need to enroll 35 patients. Ehave will be studying the effect of ketamine as a treatment for major depression while assessing the candidate therapy’s safety and tolerability.
Mental health disorders, in the wake of Covid-19, are on the rise. Depression alone affects over 264 million worldwide, and drug overdoses have risen 42% since the pandemic began.
“Ehave’s goal,” stated Alfred Farrington II, CIO of Ehave, “is to help practitioners make more informed decisions about mental health care. We believe the data from this clinical trial will provide longitudinal insights that can link brain analysis and psychedelics.”
Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the brain areas impacted by the treatment. This study has the potential to create new forms of treatment for chronic mental health disorders.
BRSF’s neurological devices, NeuroCap(TM) and NeuroEEG(TM) are portable, clinical-grade, cost-efficient, easy-to-use, and allow for long-term monitoring. In addition to these benefits, BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected.
Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.